Kate Sandstrom on Ensuring Patient Follow-Up With Radiation Oncology Teams

Patients in the CARTITUDE-4 trial experienced a high response rate to the treatment as early as their first relapse.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Older patients with cancer demonstrated a moderate to high symptom burden, leading to the need for routine symptom assessments and tailored management interventions.

Seth Eisenberg, ASN, RN, OCN, BMTCN, emphasizes the importance of reducing nurse exposure to hazardous drugs—and ongoing research efforts to improve nursing safety.

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

Patients with gastric/GEJ adenocarcinoma treated with cadonilimab plus oxaliplatin and capecitabine obtained a survival benefit regardless of PD-L1 expression.